Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,548 JPY | +0.19% | +1.64% | +10.18% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+10.18% | 3.61B | B+ | ||
+32.36% | 698B | C+ | ||
+26.51% | 568B | B | ||
-4.40% | 358B | C+ | ||
+19.46% | 328B | B- | ||
+3.50% | 283B | C+ | ||
+16.34% | 238B | B+ | ||
+6.68% | 203B | B- | ||
-9.08% | 198B | A+ | ||
+8.62% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 4536 Stock
- Ratings Santen Pharmaceutical Co., Ltd.